We report the synthesis and in vitro biological activity of the nonpeptide bradykinin receptor antagonist WIN 64338, [[4-[[2-[[bis(cyclohexylamino) Bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) is a nonapeptide released from kininogens by the actions of plasma kallikreins (1) that has been implicated in a variety of physiological and pathological processes, including pain, inflammation, and regulation of blood pressure (2, 3). The effects of bradykinin are mediated through specific G-protein-coupled cell surface receptors (4). These receptors have been tentatively divided into at least three classes, B1, B2, and B3 (5-7), on the basis of pharmacological characterization with selective bradykinin peptide agonists and antagonists. Bradykinin binds to most putative B2 receptors with an affinity in the low nanomolar range under physiological conditions (8) .
Bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) is a nonapeptide released from kininogens by the actions of plasma kallikreins (1) that has been implicated in a variety of physiological and pathological processes, including pain, inflammation, and regulation of blood pressure (2, 3) . The effects of bradykinin are mediated through specific G-protein-coupled cell surface receptors (4) . These receptors have been tentatively divided into at least three classes, B1, B2, and B3 (5-7), on the basis of pharmacological characterization with selective bradykinin peptide agonists and antagonists. Bradykinin binds to most putative B2 receptors with an affinity in the low nanomolar range under physiological conditions (8) .
A bradykinin analogue in which D-phenylalanine replaces L-proline in the 7 position of the native ligand was discovered by Vavrek and Stewart (9) and was found to be a bradykinin B2 receptor antagonist. A series of peptide analogues of bradykinin containing this substitution have demonstrated antagonist activity in a variety of tissues (10, 11) . The D-Phe7-substituted bradykinin analogues were critical for initial receptor classification; however, they are generally of low potency in various biological assays and demonstrate partial or full agonist activity in certain tissues (12) . In addition, these compounds are substrates for carboxypeptidase N (13) . Cleavage of the C-terminal arginine by carboxypeptidase N results in compounds that are inactive at the bradykinin B2 receptor but active at the bradykinin B1 receptor (14) .
The structure and pharmacological activity of a different kind of bradykinin antagonist, DArg0-[Hyp3,Thi5,DTic7,
Oic8lbradykinin (HOE-140) [Hyp, (4R)-4-hydroxyprolyl;
Thi, 3-(2-thienyl)alanyl; DTic, 1,2,3,4-tetrahydroisoquinolin-2-yl-carbonyl; Oic, (3aS,7aS)-octahydroindol-2-yl-carbonylJ, has recently been described (15, 16) . In a variety of bradykinin assays, this compound acts as a selective B2 receptor antagonist and is at least two orders of magnitude more potent than any ofthe DPhe7-substituted compounds (17, 18) . Although HOE-140 appears to be a competitive antagonist of bradykinin at the B2 receptor in some biological assays, it is reported to be noncompetitive in other systems (19, 20) .
Despite the increases in potency and biological activity observed in second-generation bradykinin receptor antagonists, these compounds are all peptides and therefore subject to metabolism and poor bioavailability (21 3 min prior to the addition of agonist. A second 0.5-ml portion of buffer with or without bradykinin (to determine background efflux levels) was added for a second 3-min incubation period to determine the agonist-stimulated efflux. The assay was terminated by removal of 0.8 ml of the reaction mixture and aspiration of the remaining buffer. After agonist stimulation (second incubation period), the cells were solubilized with 1 ml of 0.2% Triton X-100 to determine the amount of residual 45Ca2+ left in the cells. The radioactivities in the 0.8-ml reaction mixture and the 1-ml Triton X-100 aliquots from each plate were measured in 10 ml of liquid scintillation fluid for 2 min. The counts per minute (cpm) obtained for each were combined to get the total cpm of 45Ca2+ for each well. This number was then used to calculate the fractional release (cpm released divided by the total cpm) per well. Specific fractional release for each plate is defined as the fractional release induced by agonist minus the basal fractional release.
Guinea Pig Ileum Contractility Assay. Charles River, Hartley strain, guinea pigs (400-to 600-g body weight) were anesthetized with CO2 and decapitated. A section of ileum was excised and placed in warm (31°C) Krebs solution.
Lengths of ileum of approximately 3-4 cm were threaded onto a moistened glass rod and the outer longitudinal muscle was separated from the circular muscle with a cotton swab. Strips of muscle, 1.5-2 cm in length, were then mounted in a 10-ml bath containing Krebs solution (310C) and aerated with 95% 02/5% CO2. Tissue contractions were recorded isometrically on a Grass model 7D polygraph. Preparations were allowed to equilibrate for 45-60 min and then were exposed to 100 nM bradykinin to determine comparable sensitivity between individual tissues. After a 60-min washout, preparations were exposed to cumulative concentrations of bradykinin (0. 1-100 nM) and then washed every 10-15 min for another 60 min. Putative antagonists were added to the bathing fluid 10 min prior to determination of the bradykinin concentration-effect curve. Contractile effects of spasmogens or test compounds are expressed as a percent of the maximal contraction elicited by spasmogen in the first concentration-effect curve. To minimize degradation of bradykinin and to prevent responses due to neuronal activation or prostaglandin production, in experiments using bradykinin as the agonist, Krebs solutions contained 1 ,uM each of captopril, dithiothreitol, atropine, morphine, and indomethacin. In experiments using acetylcholine as the agonist, pyrilamine maleate was substituted for atropine.
Data Analysis. Unless otherwise stated, analysis of [3H]bradykinin binding data to determine values for Kd, K1, and Bma, was performed by using LIGAND (24), a nonlinear least-squares regression analysis program, on an IBM-PC computer. Preliminary IC50 values were obtained by using the program EBDA (BioSoft, Princeton, NJ). EC50 values for 45Ca2+ efflux studies were calculated by using a fourparameter curve-fitting routine in NLIN as described by DeLean et al. (25) . A two-sample t test was used to determine statistical differences when relevant.
EC50 values for bradykinin-induced contractile responses
in guinea pig ileum were determined by probit analysis of the concentration-effect curve. In instances where the maximal response (E.,) of the spasmogen in a given concentrationresponse curve differed by ± 15% or more from the spasmogen maximal effect in the initial dose-response curve, EC50 values were determined after transformation ofthe data to the reduced or increased maximal effect. A dose ratio was calculated from the EC50 of the dose-response curve in the presence of antagonist divided by the EC50 for the individual concentration-response curve of spasmogen alone for that individual tissue preparation. Statistical differences between E. values were determined by using Student's t test. (Fig. 3B) .
RESULTS
Inhibition of Agonist-Stimulated Contractility. WIN 64338 demonstrates a competitive interaction at the guinea pig ileum bradykinin B2 receptor by producing parallel rightward shifts in the bradykinin contractility concentration-response curve (Fig. 4A) . Schild analysis of the data in Fig. 4A results in a calculated pA2 of 8.2 with a slope of the Schild plot equal to -1.02 (Fig. 4B) . When tested against acetylcholineinduced contractility in the same preparation, WIN 64338 demonstrates a significant rightward shift in the concentration-response curve at a concentration of 10 uM (Fig. 5) .
Effect of WIN 64338 on Bradykinin B1 Receptors. Possible actions of WIN 64338 on bradykinin B1 type receptors were evaluated in a rabbit aortic ring contractility assay; this preparation is used extensively to characterize peptide antagonists of the B1 receptor (28) . Rabbit aortic rings were preincubated for at least 3.5 hr prior to agonist challenge to induce B1 receptor activity. The EC50 for des-Arg9-bradykinin, the classical B1 receptor agonist, was 80 nM in these experiments. WIN 64338 does not inhibit des-Arg9-bradykinin-mediated contractility, as inferred from the observation that it does not produce a rightward parallel shift of the agonist concentration-response curve at 1 or 7 ,tM (Fig.  6 ). There appears to be minor antagonism of the contractile effect at higher concentrations; the EC50 for des-Arg9- nM), weakly to the rat opiate, al-adrenergic, a2-adrenergic, and dopamine D2 receptors (1.0 ,uM > K, < 5.0 ,uM), and very weakly or not at all to the benzodiazepine, serotonin, nitrendipine, histamine H1, dopamine D1, and adenosine receptors.
DISCUSSION
There are previous reports describing inhibition of bradykinin-mediated functional responses by nonpeptide molecules. Rocha e' Silva and Leme (29) reported that cyproheptadine and imipramine produce weak inhibition of bradykinininduced contractility in the guinea pig ileum. Pyridinol carbamate produces inhibition of bradykinin-induced contractions of rat vein (30) and menadione blocks bradykinininduced bronchoconstriction in the guinea pig (31) . Findings reported by J. Calixto, R. Yunes, and their colleagues (for review see ref. 21 ) suggest that steroidal glycosides isolated from the Brazilian plant Mandevilla velutina inhibit bradykinin-mediated contractility in rat uterus and guinea pig ileum in a competitive manner. In addition, these compounds inhibit carrageenan-induced paw edema: and bradykininmediated vascular permeability. The structures of these steroidal glycosides have not been published. None of these compounds demonstrates inhibition of [3Hlbradykinin binding to a bradykinin receptor (32) , a mandatory criterion for competitive interaction with bradykinin at its receptor binding site. Proc. Natl. Acad. Sci. USA 91 (1994) Our initial screen for nonpeptide hits at the bradykinin receptor resulted in the identification of active molecules that were typically bis-charged salts, in which the two positive charges are separated by aflexible alkyl chain. Rigid analogues of these early leads were synthesized to optimize the charge separation, which was found to be approximately 10 A. This distance is consistent with the charge separation observed for the terminal arginine residues of bradykinin, based on conformational models which assume a (-turn structure in the carboxyl-terminal region (33) . In addition, previously disclosed peptide structure-activity relationship data suggest an absolute requirement of either an aromatic residue in position 8 or a D aromatic acid residue in position 7 for high-affinity binding (34) 6-fold more potent at the human IMR-90 B2 receptor (pA2 = 7.1; K, = 60 nM), suggesting that it is more selective for the bradykinin receptor.
In summary, a class of nonpeptide competitive antagonists of the human bradykinin B2 receptor has been successfully designed, with WIN 64338 emerging as a potent receptor antagonist. The two positively charged moieties and the hydrophobic naphthalene core bear structural resemblance to the positively charged terminal arginine residues (Arg1 and Arg9) and the salient hydrophobic phenylalanine residue (Phe8) in the native ligand. This class of nonpeptide B2 receptor antagonists may hold promise for the design ofother agents having enhanced receptor affinity and biological activity.
